IceCure Medical shares favorable kidney and breast cancer cryoablation data

IceCure Medical (NASDAQ:ICCM) disclosed positive clinical data evaluating its liquid-nitrogen-based ProSense cryoablation system across multiple tumor indications, showcasing the technology's long-term tumor control and high patient satisfaction metrics.

The Caesarea, Israel-based medical device manufacturer presented the findings at the European Conference on Interventional Oncology (ECIO) 2026.

The highlight of the presentation included final analysis data from the prospective, multicenter ICESECRET clinical trial, which examined the efficacy of ProSense freezing technology on localized small renal masses measuring up to 5 centimeters.

The kidney cancer study reported an overall recurrence-free rate of 83.9% at a median follow-up period of 4 years.

For patients presenting with unifocal tumors measuring 3 centimeters or smaller, the recurrence-free rate increased to 89.4%.

The procedures, performed under computed tomography (CT) guidance, demonstrated minimal impact on long-term renal function and resulted in a brief 1.3-day average post-procedure hospitalization stay.

In addition to the renal findings, IceCure highlighted data from independent studies evaluating ProSense in benign and malignant breast tumors.

A study evaluating the technology in early-stage breast cancer patients reported zero residual tumor mass on follow-up imaging at 6 and 12 months post-procedure, coupled with a 100% rate of excellent cosmetic satisfaction among participants.

Separately, a trial assessing the treatment of benign breast fibroadenomas showed a median tumor volume reduction of 80.6% at 6 months, which expanded to a 92.9% reduction at the 12-month mark.

The expanding clinical data baseline coincides with growing medical community exposure.

The conference featured its first-ever dedicated breast cryoablation master class, which exceeded its maximum registration capacity.

The clinical findings add to IceCure’s regulatory footing.

ProSense previously secured Food and Drug Administration (FDA) clearance for the local treatment of low-risk, early-stage breast cancer in women aged 70 and older alongside adjuvant endocrine therapy, providing an alternative for patients who are poor candidates for conventional surgical resection.